Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $33.
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $33.